Jamjoom Pharmaceuticals Factory Co.
TTADAWUL:4015121.40
SAR
-0.40
(-0.33%)
ISIN
SA15QGU1UNH6
Return %
Stock
S&P 500
1Y
-23.93
14.20
3Y
18.09
81.12
5Y
- -
68.34
Capital Structure
SAR
•
in mil. unless spec.Working Capital
SAR
•
in mil. unless spec.Growth Rates
SAR
•
in mil. unless spec.Quarterly Revenue
SAR
•
in mil. unless spec.Quarterly Earnings Per Share
SAR
•
in mil. unless spec.Quarterly Dividends Per Share
SAR
•
in mil. unless spec.Company Description
- CEO
- Tarek Youssef Hosni
- Full Time Employees
- 1,130
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Corniche Road Jeddah MC Saudi Arabia 21442
- IPO Date
- Jun 20, 2023
- Website
- jamjoompharma.com
- Similar Companies
- Business
- Jamjoom Pharmaceuticals Factory Company is a Saudi joint-stock company primarily engaged in the development, manufacturing, marketing, and sale of a wide range of high-quality branded generic pharmaceutical products. Founded in 2000 and headquartered in Jeddah, Saudi Arabia, the company operates state-of-the-art manufacturing facilities in Saudi Arabia, Egypt, and Algeria, with a significant production capacity exceeding 190 million units annually. Jamjoom Pharma's core product portfolio spans eight key therapeutic areas: ophthalmology, dermatology, consumer health, general medicine, gastrointestinal, cardiovascular, central nervous system, and over-the-counter (OTC) products; it has recently expanded into the anti-diabetic therapeutic area as part of its growth strategy. The company is a leading generics manufacturer in the Middle East and Africa (MEA) region, with a direct and indirect presence in 36 countries, including major markets such as Saudi Arabia, the United Arab Emirates, Egypt, and Iraq. Recent strategic developments include the launch of nine new products in 2024 across therapeutic areas such as consumer health and antibiotics, with a robust pipeline targeting high-growth sectors like cardiovascular, gastrointestinal, biologics, and biosimilars. Jamjoom Pharma signed a non-binding term sheet in late 2025 with Pharmaceutical Investment Co. (Lifera) to establish a joint venture focused on local manufacturing and expansion into vaccines, biologics, and biosimilars within Saudi Arabia. The company has also partnered for the acquisition of a pharmaceutical manufacturing plant in Algeria to expand its regional footprint and production capabilities. Over the past three years, Jamjoom Pharma has doubled its production capacity and expanded its geographic reach, achieving double-digit revenue growth in key markets including Saudi Arabia, the GCC, Iraq, North Africa, and Egypt. Jamjoom Pharma targets a broad range of customers including healthcare providers, pharmacies, and patients, offering multi-dose ophthalmic solutions, injectables, ointments, creams, oral liquids, tablets, and capsules. The company emphasizes R&D, supported by a team of over 90 scientists and PhD graduates, to innovate and bring differentiated pharmaceutical products to market. It actively supports local pharmaceutical production in line with Saudi Vision 2030 objectives, benefiting from regulatory incentives in Egypt and Algeria to become a regional hub for supply and export. Jamjoom is recognized as one of the leading generics manufacturers in its markets, notably ranking first in dermatology in Saudi Arabia and second in ophthalmology. Overall, Jamjoom Pharmaceuticals Factory Company is a leading pharmaceutical manufacturer in the MEA region, offering a diversified and expanding portfolio of branded generic products across multiple therapeutic areas, supported by recent product launches, strategic partnerships, capacity expansions, and a focus on biologics and biosimilars to sustain growth and market leadership. Its operations and strategic expansion emphasize both regional presence and enhanced production capabilities through acquisitions and joint ventures.